MOMENTUM

• Research type

  Research Study

• Full title

  A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma.

• IRAS ID

  1013134

• Contact name

  Len Reyno

• Contact email

  clinicaltrials@c4therapeutics.com

• Sponsor organisation

  C4 Therapeutics, Inc.

• Eudract number

  2025-524181-26

• Clinicaltrials.gov Identifier

  NCT07284758

• Research summary

  In this clinical study, two medicines are being used: cemsidomide and dexamethasone. Cemsidomide is a new medicine being tested, while dexamethasone is an approved medicine that supports the treatment. Both are taken as tablets by mouth.
  This study is testing if cemsidomide, taken with dexamethasone, can help people with relapsed or refractory multiple myeloma—a type of blood cancer that has come back or stopped responding to previous treatments. The study also looks at how safe the treatment is and how it affects the body.
  The study will take place at around 60 hospitals in North America, the EU and the UK, with about 100 participants in total.

• REC name

  East Midlands - Nottingham 2 Research Ethics Committee

• REC reference

  26/EM/0037

• Date of REC Opinion

  25 Mar 2026

• REC opinion

  Further Information Favourable Opinion